Stockreport

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc.  (MEIP) 
Last mei pharma, inc. earnings: 2/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.meipharma.com
PDF – Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study –– Anti-leukemic Activity Across Multiple Heavily Pr [Read more]